Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1994 May;53(5):298–303. doi: 10.1136/ard.53.5.298

A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus.

E M Hay 1, A Huddy 1, D Black 1, P Mbaya 1, B Tomenson 1, R M Bernstein 1, P J Lennox Holt 1, F Creed 1
PMCID: PMC1005327  PMID: 8017982

Abstract

OBJECTIVES--To investigate change in psychiatric disorder and change in cognitive function in patients with systemic lupus erythematosus (SLE) assessed on two occasions two years apart. METHODS--A prospective cohort study of 49 patients with SLE using standardised psychiatric and clinical research methods. RESULTS--The point prevalence of psychiatric disorder (20% and 24%), and of cognitive impairment (23% and 18%), was similar at first and second interview for the whole group. There was, however, considerable change in individual patient's psychiatric status and cognitive function: only 1/9 patients with impairment on two or more cognitive tests at first interview was still impaired at second interview. Change in cognitive function appeared to mirror change in psychiatric status. CONCLUSIONS--These findings suggest that the previously reported high prevalence of cognitive impairment in SLE may be explained by coexisting psychiatric disorder, rather than reflecting subclinical central nervous system (CNS) involvement.

Full text

PDF
298

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bernstein R. M., Steigerwald J. C., Tan E. M. Association of antinuclear and antinucleolar antibodies in progressive systemic sclerosis. Clin Exp Immunol. 1982 Apr;48(1):43–51. [PMC free article] [PubMed] [Google Scholar]
  2. Bridges A. J., Burns R. P. Acute iritis associated with primary Sjögren's syndrome and high-titer anti-SS-A/Ro and anti-SS-B/La antibodies. Treatment with combination immunosuppressive therapy. Arthritis Rheum. 1992 May;35(5):560–563. doi: 10.1002/art.1780350511. [DOI] [PubMed] [Google Scholar]
  3. Carbotte R. M., Denburg S. D., Denburg J. A. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Ment Dis. 1986 Jun;174(6):357–364. doi: 10.1097/00005053-198606000-00008. [DOI] [PubMed] [Google Scholar]
  4. Dean C., Surtees P. G., Sashidharan S. P. Comparison of research diagnostic systems in an Edinburgh community sample. Br J Psychiatry. 1983 Mar;142:247–256. doi: 10.1192/bjp.142.3.247. [DOI] [PubMed] [Google Scholar]
  5. Ginsburg K. S., Wright E. A., Larson M. G., Fossel A. H., Albert M., Schur P. H., Liang M. H. A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum. 1992 Jul;35(7):776–782. doi: 10.1002/art.1780350711. [DOI] [PubMed] [Google Scholar]
  6. Hanly J. G., Fisk J. D., Sherwood G., Jones E., Jones J. V., Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol. 1992 Apr;19(4):562–567. [PubMed] [Google Scholar]
  7. Hanly J. G., Walsh N. M., Fisk J. D., Eastwood B., Hong C., Sherwood G., Jones J. V., Jones E., Elkon K. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br J Rheumatol. 1993 Apr;32(4):291–296. doi: 10.1093/rheumatology/32.4.291. [DOI] [PubMed] [Google Scholar]
  8. Hay E. M., Bacon P. A., Gordon C., Isenberg D. A., Maddison P., Snaith M. L., Symmons D. P., Viner N., Zoma A. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993 Jul;86(7):447–458. [PubMed] [Google Scholar]
  9. Jenkins R., Mann A. H., Belsey E. The background, design and use of a short interview to assess social stress and support in research and clinical settings. Soc Sci Med E. 1981 Aug;15(3):195–203. doi: 10.1016/0271-5384(81)90013-2. [DOI] [PubMed] [Google Scholar]
  10. Klotz J. L., Minami R. M., Teplitz R. L. An enzyme-linked immunosorbent assay for antibodies to native and denatured DNA. J Immunol Methods. 1979;29(2):155–165. doi: 10.1016/0022-1759(79)90065-6. [DOI] [PubMed] [Google Scholar]
  11. Lim L., Ron M. A., Ormerod I. E., David J., Miller D. H., Logsdail S. J., Walport M. J., Harding A. E. Psychiatric and neurological manifestations in systemic lupus erythematosus. Q J Med. 1988 Jan;66(249):27–38. [PubMed] [Google Scholar]
  12. Long A. A., Denburg S. D., Carbotte R. M., Singal D. P., Denburg J. A. Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. Ann Rheum Dis. 1990 Apr;49(4):249–253. doi: 10.1136/ard.49.4.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Papero P. H., Bluestein H. G., White P., Lipnick R. N. Neuropsychologic deficits and antineuronal antibodies in pediatric systemic lupus erythematosus. Clin Exp Rheumatol. 1990 Jul-Aug;8(4):417–424. [PubMed] [Google Scholar]
  14. Snowden N., Wilson P., Pumphrey R. Anticardiolipin antibodies in systemic lupus erythematous. Ann Rheum Dis. 1989 Jan;48(1):80–82. doi: 10.1136/ard.48.1.80-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  16. Wekking E. M., Nossent J. C., van Dam A. P., Swaak A. J. Cognitive and emotional disturbances in systemic lupus erythematosus. Psychother Psychosom. 1991;55(2-4):126–131. doi: 10.1159/000288419. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES